{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["130(9)"],"submitter":["Ott MG"],"pubmed_abstract":["The trifunctional antibody catumaxomab is a targeted immunotherapy for the intraperitoneal treatment of malignant ascites. In a Phase II/III trial in cancer patients (n = 258) with malignant ascites, catumaxomab showed a clear clinical benefit vs. paracentesis and had an acceptable safety profile. Human antimouse antibodies (HAMAs), which could be associated with beneficial humoral effects and prolonged survival, may develop against catumaxomab as it is a mouse/rat antibody. This post hoc analysis investigated whether there was a correlation between the detection of HAMAs 8 days after the fourth catumaxomab infusion and clinical outcome. HAMA-positive and HAMA-negative patients in the catumaxomab group and patients in the control group were analyzed separately for all three clinical outcom"],"journal":["International journal of cancer"],"pagination":["2195-203"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3415680"],"repository":["biostudies-literature"],"pubmed_title":["Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites."],"pmcid":["PMC3415680"],"pubmed_authors":["Lindhofer H","Seimetz D","Marme F","Hennig M","Moldenhauer G","Spannagl R","Linke R","Essing MM","Ott MG"],"additional_accession":[]},"is_claimable":false,"name":"Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.","description":"The trifunctional antibody catumaxomab is a targeted immunotherapy for the intraperitoneal treatment of malignant ascites. In a Phase II/III trial in cancer patients (n = 258) with malignant ascites, catumaxomab showed a clear clinical benefit vs. paracentesis and had an acceptable safety profile. Human antimouse antibodies (HAMAs), which could be associated with beneficial humoral effects and prolonged survival, may develop against catumaxomab as it is a mouse/rat antibody. This post hoc analysis investigated whether there was a correlation between the detection of HAMAs 8 days after the fourth catumaxomab infusion and clinical outcome. HAMA-positive and HAMA-negative patients in the catumaxomab group and patients in the control group were analyzed separately for all three clinical outcom","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 May","modification":"2025-05-29T19:39:45.496Z","creation":"2019-03-27T00:56:35Z"},"accession":"S-EPMC3415680","cross_references":{"pubmed":["21702044"],"doi":["10.1002/ijc.26258"]}}